Skip to content

Released Aug 13, 2020, during market hours

10-Q filed Aug 13, 2020, 44 days after period end · 0001564590-20-039951

Q2 2020 · 10-Q
Revenue—
Net Income-$5.56MN/M vs Q2 2019N/M vs Q1 2020
EPS Diluted-$0.41N/M vs Q2 2019N/M vs Q1 2020
Operating Income-$5,070,000N/M
Operating Cash Flowderived-$5,300,000—
Free Cash Flowderived-$5,304,000—

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

MetricQ2 2020Q2 2019
Net Income-$5.56M-$8.81M
EPS Diluted-$0.41-$1.33

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Compass Therapeutics, Inc. · CIK 1738021 · Engraved from SEC EDGAR